Clinical trials
Phase 1 Lupus Nephritis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
51 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2014 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 11 |
| 2025 | 17 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 17 |
| Completed | 11 |
| Active, not recruiting | 5 |
| Not yet recruiting | 5 |
| Withdrawn | 4 |
| Enrolling by invitation | 3 |
| Terminated | 3 |
| Unknown status | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 4 |
| Bristol-Myers Squibb | 2 |
| Hospital for Special Surgery, New York | 2 |
| Takeda | 2 |
| Tongji Hospital | 2 |
| Zhejiang University | 2 |
| Adicet Therapeutics | 1 |
| Ain Shams University | 1 |
| Air Force Military Medical University, China | 1 |
| Alexion Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lupus Nephritis | 51 |
| Lupus Erythematosus, Systemic | 30 |
| Scleroderma, Systemic | 13 |
| Autoimmune Diseases | 12 |
| Myositis | 12 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 8 |
| Scleroderma, Diffuse | 7 |
| Dermatomyositis | 5 |
| Antiphospholipid Syndrome | 3 |
| Arthritis, Rheumatoid | 3 |
Trials
Showing 51 to 51 of 51. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.